TELO Telomir Pharmaceuticals Inc Total Asset Value of Company

TELO (Telomir Pharma) - company brandmark

Telomir Pharmaceuticals (TELO) operates as a life-extension startup, fully outsourcing substance synthesis and preclinical trials to external contractors. This chart illustrates a market valuation of total assets at 27.41. Such a model minimizes capital expenditures during the initial stage. Meanwhile, Telomir Pharmaceuticals (TELO) is implementing algorithmization to combat cellular aging, although the final testing stage and medical supervision remain under human control.

TELO (Telomir Pharmaceuticals) Company Total Assets history from 02/21/2024 to 10/31/2026

Analytical breakdowns and data insights for company Telomir Pharma (TELO)

- stock value and consensus price forecast:
Market Price telomirpharma.com|TELO - Price Target Chart
- market capitalization data:
Market Valuation Telomir Pharmaceuticals Corp|TELO - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Telomir Pharmaceuticals|TELO - Book Capitalization|Market Capitalization to Book Value Ratio telomirpharma.com|TELO - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Telomir Pharmaceuticals|TELO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Telomir Pharmaceuticals Corp|TELO - Company Aggregate Debts|Debts to Book Capitalization Telomir Pharmaceuticals Corp|TELO - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Telomir Pharmaceuticals|Immediate Liquidity telomirpharma.com
- net income and valuation multiples indicators:
TELO - Net Income
Fundamental valuation:Telomir Pharmaceuticals
Manufactured products of Telomir Pharmaceuticals

This indicator reflects the dynamic market value of all Telomir Pharmaceuticals (TELO) resources, calculated inversely via ROA to assess the current capital volume accounting for technological revaluation. An analysis of total asset value confirms that in longevity biotechnologies, asset value depends on scientific breakthroughs rather than macroeconomic cycles, determining the fundamental stability of investment capital.

Key competitors

Company Assets haleon.com (HLN)|Aggregate Company Assets Kenvue|Verona Pharma PLC - Total Asset Value of Company|Company Total Assets MENS|LGND (Ligand Corp) - Aggregate Asset Value|Company Total Assets AMRX (Amneal Pharmaceuticals)|Company Total Assets perrigo.com PRGO|ALVO - Aggregate Company Assets|Aggregate Asset Value LQDA (Liquidia Corp)|Galapagos Genomics (GLPG) - Aggregate Company Assets|Cumulative Company Assets ANI Pharmaceuticals Corp|MNKD (MannKind Corporation) - Company Total Assets|Company Total Assets amphastar.com|Cumulative Company Assets PCRX (Pacira BioSciences, Inc.)|SPRY (ARS Pharmaceuticals Inc) - Aggregate Asset Value|Aggregate Company Assets Theravance TBPH|Aquestive Corp (AQST) - Company Assets|SCPH: Cumulative Company Assets|Tectonic Therapeutic, Inc. - Aggregate Business Assets|TNXP: Company Total Assets|China SXT Pharmaceuticals, Inc. - Aggregate Asset Value|EPRX (Eupraxia Pharmaceuticals, Inc.) - Company Total Assets|Company Assets BioHarvest Sciences Inc BHST|Aggregate Company Assets eXoZymes Inc (EXOZ)|ORMP (oramed.com) - Aggregate Asset Value|Entera Bio - Cumulative Company Assets|Aggregate Business Assets HYFT (MindWalk Holdings, Inc.)|ABVC BioPharma Inc - Company Total Assets|Company Assets Cumberland Corp|Quantum BioPharma Ltd (QNTM) - Aggregate Company Assets|FGEN (fibrogen.com) - Aggregate Company Assets|Aggregate Company Assets Rani Therapeutics Holdings|Company Assets Synergy CHC Corporation SNYR|Aggregate Company Assets Rallybio Corporation (RLYB)|Cumulative Company Assets lexariabioscience.com LEXX|Company Total Assets PULM (Pulmatrix, Inc.)|Company Total Asset Base Pheton Holdings Limited (PTHL)|APM - Aggregate Company Assets|Aggregate Asset Value LYRA (Lyra Therapeutics Inc.)|IBO (Impact BioMedical) - Cumulative Company Assets|TNF Pharmaceuticals, Inc. - Aggregate Asset Value|Aggregate Company Assets cbdMD Inc.|painreform.com - Total Asset Value of Company|Company Total Assets CYTO|LIPO (Lipella Pharmaceuticals Inc) - Aggregate Asset Value|Company Total Assets OPTN (Optinose)|Company Total Assets Pieris Pharma PIRS|PROC - Aggregate Company Assets|Aggregate Asset Value PTPI (petrospharma.com)|Qilian International Holding (QLI) - Aggregate Company Assets|Cumulative Company Assets Acelyrin Inc.|TFFP (TFF Pharma) - Company Total Assets